Brief: Nasdaq Granted Citius Pharmaceuticals' Request For Extension To Evidence Compliance Listing Requirement
13/03/2024 20:52
March 13 (Reuters) - Citius Pharmaceuticals Inc
CTXR.O :
* CITIUS PHARMACEUTICALS-ON MARCH 12 GOT FORMAL NOTICE
NASDAQ
GRANTED REQUEST FOR EXTENSION THROUGH SEPT 9 TO EVIDENCE
COMPLIANCE LISTING REQUIREMENT
Source text for Eikon: ID:n0001213900-24-022184
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules